The board of directors of the Shanghai Henlius Biotech, Inc. (Company) announced that on 4 January 2021, the Company entered into a license agreement (the "Agreement") with Intas, pursuant to which the Company agreed to grant Intas an exclusive license to commercialise HLX02 Trastuzumab injection in the United States of America (the "USA") and Canada (the "Territory"). Parties: Shanghai Henlius Biotech, Inc. is Licensor and Intas is Licensee. Licensed Product: HLX02 Trastuzumab injection, 60mg/vial, 150mg/vial, and 420mg/vial, powder, lyophilized, for solution. Collaboration and License Licensor will grant Licensee: the exclusive rights to use the product dossiers and Licensor 's relevant intellectual property rights of the Licensed Product for the application of marketing authorisations in the Territory, including the right to grant sublicenses; the exclusive rights to commercialise the Licensed Product in the Territory; and to practice the licensed technology rights in connection with such commercialisation of the Licensed Product in the Territory; the non-exclusive rights to develop and manufacture the Licensed Product in or outside the Territory (including, but not limited to, in India) for the sole purpose of exercising the Licensee' rights. Milestone Payments and Royalties: upfront payment of $27 million upon date of the Agreement; regulatory milestone payments of not more than $13 million in total, payable according to the pharmacokinetic study progress as required by the United States Food and Drug Administration (FDA) and marketing application of the Licensed Product in the USA; and after commercialisation of the Licensed Product in the Territory, commercial sales milestone payments of $25 million for every $500 million of cumulative net sales of the Licensed Products in the Territory.